Equities

Cuorips Inc

4894:TYO

Cuorips Inc

Actions
  • Price (JPY)7,110.00
  • Today's Change-100.00 / -1.39%
  • Shares traded118.80k
  • 1 Year change+297.21%
  • Beta--
Data delayed at least 20 minutes, as of Jul 30 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cuorips Inc is a Japan-based company mainly engaged in the development and commercialization of regenerative medical products and contract development and manufacturing organization (CDMO) business. The main product of the Company is human iPS cell-derived cardiomyocyte sheets. The Company provides regenerative medical products for the heart and other areas through in-house research, joint research with universities and other research institutions and major pharmaceutical companies. The Company operates CDMO business using CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept.

  • Revenue in JPY (TTM)23.10m
  • Net income in JPY-632.18m
  • Incorporated2017
  • Employees59.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fuji Pharma Co Ltd43.05bn5.92bn34.43bn1.62k5.710.76753.740.7998243.57243.571,771.381,812.380.50711.343.2126,558,910.006.974.1010.565.5839.7842.4113.757.550.5895--0.382631.1715.421.5227.410.370919.045.73
Daito Pharmaceutical Co Ltd46.90bn3.30bn37.27bn1.01k11.290.69737.650.7947210.18210.182,988.733,404.720.63261.892.96--4.296.275.588.2420.9822.656.788.471.11--0.14318.483.982.66-8.47-1.2711.3711.67
Seikagaku Corp36.21bn2.19bn50.05bn988.0021.980.66513.001.3840.0840.08663.801,324.810.46012.065.0236,652,840.002.780.42613.050.467846.6054.186.040.98144.47--0.0055465.788.244.99-2.24-0.522430.280.00
Cuorips Inc23.10m-632.18m57.67bn59.00--9.58--2,496.17-86.04-86.043.14752.260.00474.6617.57391,559.30-12.94---13.30--41.69---2,736.49--33.80--0.00---39.65---39.84------
ASKA Pharmaceutical Holdings Co Ltd62.84bn7.55bn70.69bn762.008.681.066.931.12266.48266.482,219.582,186.080.70661.694.0882,471,130.008.484.6311.085.8748.8046.9412.016.761.49--0.132814.863.946.1278.0334.04-37.8923.36
Katakura Industries Co., Ltd.39.83bn3.01bn73.53bn1.04k22.970.897112.491.8590.9090.901,203.272,327.460.28582.354.4938,300,000.002.292.352.993.3438.3037.758.018.322.58--0.109718.8116.62-2.048.0918.87-7.4610.76
JCR Pharmaceuticals Co Ltd42.87bn5.51bn81.70bn934.0014.351.409.351.9143.9243.92342.31450.130.43490.58913.2945,900,430.005.628.668.4713.4672.9074.5112.9218.241.2227.690.293230.6024.8313.1146.008.1918.5421.67
Data as of Jul 30 2024. Currency figures normalised to Cuorips Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.24%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 04 Jul 202419.20k0.24%
Data from 11 Jul 2024 - 11 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.